Jaguar Health says topline results for trial of crofelemer are ‘forthcoming’

Jaguar Health announced the voting results of the Company’s Special Meeting of Stockholders held on April 9: Four proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. “As we announced last week, the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market has granted Jaguar an additional grace period, through August 13, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Although we do not intend to effect a reverse split of the Company’s issued and outstanding voting common stock at present, seeking the discretion to implement actions, if necessary to maintain Jaguar’s Nasdaq listing, is an important responsibility of the Board, and we are grateful to our shareholders for voting to approve the related proposal,” said Lisa Conte, Jaguar’s president, and CEO. Jaguar’s paramount near-term clinical activity is the Company’s Phase 3 pivotal OnTarget trial of crofelemer for the follow-on indication of the preventative treatment of cancer therapy-related diarrhea. Top line results from this pivotal study are forthcoming